Anti-PCSK9 monoclonal antibody
US11390688B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2017 |
| Grant date | Jul 19, 2022 |
| Priority date | — |
| Expiry date | Dec 29, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method, and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2, 3 regions; and finally the monoclonal antibodies having high affinity are screened. The PCSK9 antibody obtained by the application has good affinity to PCSK9 and can inhibit the binding of PCSK9 with its ligand and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombotic occlusion diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.